Panmira Pharmaceuticals, LLC

Amira Pharmaceuticals, Inc.

Merck + Co., Inc.

Tempest Therapeutics, Inc.

Inception 2, Inc.

Brickell Biotech, Inc.

Merck Sharp + Dohme Corp.

Inception Orion, Inc.

Brian Andrew Stearns

John Howard Hutchinson

Jeannie M Arruda

Nicholas Simon Stock

Yen Truong

Bowei Wang

Thomas Jon Seiders

Ryan Christopher Clark

Deborah Volkots

Jill Melissa Scott

Jeffrey Roger Roppe

Lucy Xiumin Zhao

Austin Chih-Yu Chen

Jill Melissa Baccei

Benito Munoz

Yalda Mostofi Bravo

Brian T Campbell

Jason Duarte Jacintho

Heather Renee Coate

Lida R Tehrani

Petpiboon Peppi Prasit

Yiwei Li

Jason Edward Brittain

Christopher David King

Thomas Jonathan Seiders

Nicholas D Smith

Jean-Michel Andre Vernier

Dehua Huang

Mustapha Haddach

Nicholas David Cosford

Timothy Andrew Parr

Mark Moran

Jillian Frances Evans

Kevin Ross Holme

Jasmine Eleanor Zunic

David Nathan Zalatan

Mark T Bilodeau

Jun Liang

Mark E Layton

Peter J Manley

Tony Siu

Nicholas D P Cosford

Essa H Hu

Jacob M Hoffman

Celine Bonnefous

Kevin J Rodzinak

Xiumin Zhao

Rowena Villanueva Cube

Yem Pham Truong

Janet Lorraine Gunzer

Tao Hu

Naomi Burke Anker

Yen Pham Truong

The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

Triazolone compounds and uses thereof

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Polycyclic compounds as lysophosphatidic acid receptor antagonists

Described herein is the DPantagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DPantagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

DP2 antagonist and uses thereof

Compounds as lysophosphatidic acid receptor antagonists

Described herein is the DPantagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4&#x2032;-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist.

The invention disclosed herein is direct to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in treating neurodegenerative diseases and promoting the generation or survival of neurons in the mammalian brain. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to a method of promoting the generation or survival of neurons in a patient in need thereof in neurodegenerative and related diseases. 

Tricyclic compounds useful as neurogenic and neuroprotective agents

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGDreceptors. Also described herein are methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

[object Object]

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGDreceptors described herein, as well as methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Growing community of inventors

Encinitas, CA, United States of America

Brian Andrew Stearns